BERLIN, Oct. 2 (Xinhua) -- Germany's Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich-Institut (PEI), approved the third clinical trial of a potential COVID-19 vaccine on Friday.
The vaccine candidate was developed by the German Center for Infection Research (DZIF) and the pharmaceutical company IDT Biologika. During the Phase-1 trial, 30 healthy adult volunteers between 18 and 55 years would receive two vaccinations at a four-week interval, according to PEI.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
